Spectrofluorometric Analysis of New-Generation Antidepressant Drugs in Pharmaceutical Formulations, Human Urine, and Plasma Samples

Table 3

Evaluation of accuracy and precision of the proposed method in pharmaceutical formulations.

Amount added (ng/mL)	Intraday		Interday
	Found	(%) Recovery	Found	(%) Recovery
	(ng/μL) ± SD^1	± RSD^3	(ng/μL) ± SD^1	± RSD^3
SER
10	9.38±0.095	93.80±1.83	8.50±0.062	85.0±2.79
50	49.25±0.089	98.50±3.51	47.42±0.106	94.84±3.98
100	98.97±0.065	98.57±5.71	98.98±0.077	98.98±5.04
PAR
10	9.43±0.066	94.30±1.36	09.08±0.176	90.80±1.45
50	49.05±0.087	98.10±2.73	49.07±0.096	98.14±3.55
100	99.44±0.061	99.44±4.58	98.88±0.138	98.88±5.38
CIT
10	9.80±0.050	98.0±1.65	8.32±0.159	83.20±2.26
50	48.89±0.070	97.78±2.15	48.89±0.111	97.78±5.17
100	99.17±0.033	99.17±5.11	98.22±0.109	98.22±6.43
VLF
10	8.57±0.104	85.70±2.45	8.66±0.130	86.60±1.13
50	48.59±0.076	97.18±3.12	47.69±0.153	95.38±4.17
100	98.98±0.126	98.98±3.87	98.84±0.111	98.84±5.43
FLX
10	8.70±0.078	87.0±1.39	7.90±0.026	79.0±2.92
50	48.77±0.103	97.54±2.73	48.54±0.165	97.08±5.74
100	98.69±0.076	98.69±5.91	97.74±0.053	98.69±6.19

¹Average of six replicate determinations and their standard deviation, ²RSD: relative standard deviation.